14-methyl-20-oxa-5-7-14-26-tetraazatetracyclo(19.3.1.1(2-6).1(8-12))heptacosa-1(25)-2(26)-3-5-8(27)-9-11-16-21-23-decaene and Primary-Myelofibrosis

14-methyl-20-oxa-5-7-14-26-tetraazatetracyclo(19.3.1.1(2-6).1(8-12))heptacosa-1(25)-2(26)-3-5-8(27)-9-11-16-21-23-decaene has been researched along with Primary-Myelofibrosis* in 1 studies

Other Studies

1 other study(ies) available for 14-methyl-20-oxa-5-7-14-26-tetraazatetracyclo(19.3.1.1(2-6).1(8-12))heptacosa-1(25)-2(26)-3-5-8(27)-9-11-16-21-23-decaene and Primary-Myelofibrosis

ArticleYear
Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.
    Chimia, 2015, Volume: 69, Issue:3

    The powerful olefin metathesis reaction was employed for the construction of late-phase clinical agents SB1317 and SB1518. In both cases RCM seems to proceed only in the presence of an acid and to predominantly furnish trans isomers. In case of SB1518 it proceeded in the presence of acid HCl, while for SB1317, it mainly proceeds in the presence of TFA (trifluroacetic acid).

    Topics: Antineoplastic Agents; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclization; Heterocyclic Compounds, 4 or More Rings; Humans; Janus Kinase 2; Lymphoma; Molecular Structure; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Stereoisomerism

2015